Pipeline
As we think about the future of medicine, we’re exploring new frontiers across a diverse and robust range of product candidates and disease areas to enable clinicians to Find, Fight and Follow® disease to deliver better patient outcomes. With a strong focus on oncology, neurology and cardiology, and a more than 70-year history as pioneers in radiopharmaceuticals, we are building a focused pipeline aligned to areas of high unmet need.
Pipeline updated June 2026
Oncology
| Candidate | Target | Isotope | Indication/Disease Area | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 | Reg. Filing |
|---|---|---|---|---|---|---|---|---|
| LNTH-2501 | Target: SSTR | Isotope: 68Ga |
Indication/Disease Area: Neuroendocrine tumors |
Phase: Reg. Filing
|
||||
|
LNTH-2501 is a diagnostic kit for the preparation of Ga-68 edotreotide Injection, indicated for use with PET imaging for the localization of somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs) in adult and pediatric patients. |
||||||||
| LNTH-24011 | Target: GRPR | Isotope: 68Ga |
Indication/Disease Area: Prostate cancer |
Phase: Phase 2
|
||||
|
LNTH-2401 is a novel radiodiagnostic targeting the gastrin-releasing peptide receptor. |
||||||||
| LNTH-2503 | Target: CCK2R | Isotope: 68Ga |
Indication/Disease Area: Small cell lung cancer |
Phase: Phase 1
|
||||
|
LNTH-2503 is a highly specific peptide vector radiodiagnostic, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC). |
||||||||
| LNTH-1363S* | Target: FAP | Isotope: 64Cu |
Indication/Disease Area: Sarcoma/GI |
Phase: Phase 1
|
||||
|
LNTH-1363S is a fibroblast activation protein, copper-64 labeled radiodiagnostic with broad potential imaging applicability and use in oncology. Learn more about our clinical trial. |
||||||||
| LNTH-2507 | Target: Undisc. | Isotope: 68Ga |
Indication/Disease Area: Pancreatic ductal adenocarcinoma |
Phase: Preclinical
|
||||
|
LNTH-2507 is a radiodiagnostic tracer targeting a cell surface molecule for the diagnosis of pancreatic ductal adenocarcinoma (PDAC). |
||||||||
| PNT2003† | Target: SSTR | Isotope: 177Lu |
Indication/Disease Area: Gastroenteropancreatic neuroendocrine tumors |
Phase: Reg. Filing
|
||||
|
PNT2003 is a somatostatin receptor targeted radiotherapeutic, in development for gastroenteropancreatic neuroendocrine tumors. |
||||||||
| LNTH-2403 | Target: LRRC15 | Isotope: 177Lu |
Indication/Disease Area: Relapsed/refractory osteosarcoma |
Phase: Phase 1
|
||||
|
LNTH-2403 is a leucine-rich repeat-containing protein 15 targeted radiotherapeutic. It received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for the treatment of osteosarcoma. Learn more about our clinical trial. |
||||||||
| LNTH-2503 | Target: CCK2R | Isotope: 177Lu |
Indication/Disease Area: Small cell lung cancer |
Phase: Phase 1
|
||||
|
LNTH-2503 is a highly specific peptide vector radiotherapeutic, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC). |
||||||||
| LNTH-24022 | Target: GRPR | Isotope: 177Lu |
Indication/Disease Area: Metastatic prostate cancer |
Phase: Preclinical
|
||||
|
LNTH-2402 is a novel gastrin-releasing peptide receptor targeted radiotherapeutic for solid tumors including prostate, breast, lung and other cancers. |
||||||||
| LNTH-2507 | Target: Undisc. | Isotope: 177Lu |
Indication/Disease Area: Pancreatic ductal adenocarcinoma |
Phase: Preclinical
|
||||
|
LNTH-2507 is a radiotherapeutic targeting a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC). |
||||||||
Neurology
| Candidate | Target | Isotope | Indication/Disease Area | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 | Reg. Filing |
|---|---|---|---|---|---|---|---|---|
| MK-6240* (florquinitau) | Target: Tau | Isotope: 18F |
Indication/Disease Area: Alzheimer’s disease |
Phase: Reg. Filing
|
||||
|
Florquinitau is a next-generation tau-targeting radiodiagnostic for Alzheimer’s disease. |
||||||||
| NAV-4694* (flutafuranol) | Target: ß amyloid | Isotope: 18F |
Indication/Disease Area: Alzheimer’s disease |
Phase: Phase 3
|
||||
| LNTH-2620/PI-2620 | Target: Tau | Isotope: 18F |
Indication/Disease Area: Alzheimer’s disease |
Phase: Phase 3
|
||||
|
LNTH-2620/PI-2620 is an F-18 labeled small molecule specifically targeting tau used as a radiodiagnostic in conjunction with PET imaging to show aggregated tau protein in people with Alzheimer’s disease and other tauopathies. It binds to both isoforms of tau (4R and 3R/4R repeats). The FDA has granted Fast Track designation for the development of LNTH-2620/PI-2620 in Alzheimer’s disease (AD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Learn more about our clinical trial. |
||||||||
Cardiology
| Candidate | Target | Isotope | Indication/Disease Area | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 | Reg. Filing |
|---|---|---|---|---|---|---|---|---|
| LNTH-2515 (florbetaben) | Target: Amyloid | Isotope: 18F |
Indication/Disease Area: Cardiac AL amyloidosis |
Phase: Phase 3
|
||||
|
LNTH-2515 (florbetaben) is an F-18 labeled radiodiagnostic stilbene derivative that binds to amyloid deposits and is being studied in patients with cardiac amyloidosis. The FDA has granted Fast Track designation for the development of LNTH-2515 (florbetaben) imaging for the diagnosis of AL (amyloid light chain) and ATTR (transthyretin amyloid cardiomyopathy) cardiac amyloidosis. Learn more about our clinical trial. |
||||||||
| LNTH-2513/GP-1 | Target: GPIIb-IIIa | Isotope: 18F |
Indication/Disease Area: Thromboembolism |
Phase: Phase 2
|
||||
|
LNTH-2513/GP-1 is a small F-18 labeled molecule, specifically designed to image active thrombi (new blood clots) by binding to activated GPllb/llla receptors, which are involved in thrombus formation and propagation. LNTH-2513 (GP1) is the first PET tracer shown to be able to detect acute thromboembolic events in humans. |
||||||||
Each of these product candidates is an investigational drug that has not yet been approved as safe and effective.
GRPR, Gastrin-releasing peptide receptor; SSTR, Somatostatin receptor; FAP, Fibroblast activation protein; CCK2R, Cholecystokinin-2 receptor; LRRC15, Leucine-rich repeat-containing protein 15; GPIIb-IIIa, Glycoprotein IIb-IIIa.
1. Also known as 68Ga-RM2. 2. Also known as 177Lu-RM2.
*We are actively partnering with researchers on these assets to provide appropriate biomarkers in relevant studies. If interested, please contact biomarkers@lantheus.com for more information.
†PNT2003 received tentative FDA approval on March 2, 2026. Final FDA approval has not yet been granted. Final approval is contingent upon resolution of outstanding regulatory and legal matters.
